ABSTRACTClostridium difficileinfection (CDI) is responsible for most of the definable cases of antibiotic- and hospital-associated diarrhea worldwide and is a frequent cause of morbidity and mortality in older patients.C. difficile, a multidrug-resistant anaerobic pathogen, causes disease by producing toxins A and B, which are controlled by an accessory gene regulator (Agr) quorum signaling system. SomeC. difficilestrains encode two Agr loci in their genomes, designatedagr1andagr2. Theagr1locus is present in all of theC. difficilestrains sequenced to date, whereas theagr2locus is present in a few strains. The functional roles ofagr1andagr2inC. difficiletoxin regulation and pathogenesis were unknown until now. Using allelic exchange, we deleted components of bothagrloci and examined the mutants for toxin production and virulence. The results showed that theagr1mutant cannot produce toxins A and B; toxin production can be restored by complementation with wild-typeagr1. Furthermore, theagr1mutant is able to colonize but unable to cause disease in a murine CDI model. These findings have profound implications for CDI treatment because we have uncovered a promising therapeutic target for the development of nonantibiotic drugs to treat this life-threatening emerging pathogen by targeting the toxins directly responsible for disease.IMPORTANCEWithin the last decade, the number of cases ofC. difficileinfections has been increasing exponentially in the United States, resulting in about 4.8 billion U.S. dollars in health care costs annually. As a multidrug-resistant, spore-forming, anaerobic pathogen,C. difficileoverpopulates the colon after the gut microbiota has been altered by antibiotic therapy. With increasing resistance to antibiotic treatment ofC. difficileinfections, patients are experiencing higher costs of health care and a lower quality of life as treatment options decrease. During infection,C. difficileproduces toxins A and B, which directly cause disease. As a result, the toxins have become promising nonantibiotic treatment targets. Here, we have identified a pathway responsible for activating the production of the toxins. This important finding opens up a unique therapeutic target for the development of a novel nonantibiotic therapy forC. difficileinfections.